Introduction {#s1}
============

Severe acute respiratory syndrome virus 2 (SARS-CoV-2) causes a respiratory disease that led to the fatal Coronavirus disease 2019 (COVID-19) pandemic. In late 2019, the SARS-CoV-2 outbreak was first reported in Wuhan, China that later led to a true crisis worldwide (Huang et al., [@B29]). Coronaviruses (CoVs) are large enveloped non-segmented positive-sense RNA viruses. They generally cause mild enteric and respiratory diseases in animals and humans (Glass et al., [@B19]). Most human CoVs, such as hCoV-229E, OC43, NL63, and HKU1 usually cause only mild respiratory diseases (Fouchier et al., [@B15]). SARS-CoV-2 causes acute, highly lethal pneumonia with clinical symptoms similar to those reported for SARS-CoV and MERS-CoV-2 (Fouchier et al., [@B15]). In contrast to SARS-CoV, SARS-CoV-2-infected patients rarely show prominent upper respiratory tract signs and symptoms. On presentation, most infected individuals exhibit dry cough (83--99%), and dyspnea (59.4--82%) with findings of bilateral ground-glass opacities on radiographic images (Guo et al., [@B23]; Huang et al., [@B29]). In most severe cases the characteristic symptom is respiratory distress (\~55%) Grasselli et al.

The reported mortality varies based on race, sex, age, and comorbid conditions (Baud et al.; Porcheddu et al., [@B60]). Currently the true mortality still is not well-established, as the mortality may occur up to 30 days post infection. Based on current literature, most severe SARS-CoV-2 cases progressed within 14--21 days after disease onset. Various laboratory abnormalities have been observed even preceding the significant respiratory dysfunction (Lu et al., [@B45]). Mortality related to SARS-CoV-2 in China as reported by the WHO is about 3.4% (Guo et al., [@B23]; Sohrabi et al., [@B71]). The most severe cases have been predominantly reported in elderly or subjects with preexisting conditions, predominantly cardiovascular diseases such as hypertension and congestive heart failure (Zhou et al., [@B88]). Interestingly, these risk factors are similar to the reported risk factors (diabetes, hypertension, obesity) associated with MERS-CoV related mortality, although MERS-CoV respiratory disease occurred in younger individuals (Assiri et al., [@B1]; World Health Organization, [@B84]). These clinical and epidemiological observations may provide some direction on the mechanism of disease. Recent reports indicate that a significant portion of SARS-CoV-2 related hospitalization in the USA are below the age of 50 years. Given the fact of a higher prevalence of metabolic diseases, including obesity, hypertension, cardiovascular diseases and diabetes in the US population (Moore et al., [@B53]), this infection may cause higher mortality. The virus gains entrance into its host cell via the ACE2 receptor. How the known epidemiological and clinical manifestation of SARS-CoV-2 infection may be explained by perturbations of physiological functions of the ACE2 receptor due to receptor virus interaction will be discussed in this manuscript.

SARS-CoV-2 Host Interaction {#s2}
===========================

SARS-CoV-2 is single-stranded positive-sense RNA virus, containing \~26--32 kilobase (kb) genome. The viral envelope consists of a lipid bilayer, where the viral membrane (M), envelope (E), and spike (S) structural proteins are anchored. Unlike other corona viruses, SARS-CoV-2 does not use aminopeptidase N (APN) and dipeptidyl peptidase 4 (DPP4) as a receptor (Raj et al., [@B61]). Similar to SARS-CoV, SARS-CoV-2 utilizes a novel metallocarboxyl peptidase angiotensin receptor (ACE) 2 to gain entry into human cells (Donoghue et al., [@B13]; Turner et al., [@B75]; Li et al., [@B41]). Similar to other CoV, during viral entry into the host cell, the spike proteins (S) on the envelope of SARS-CoV-2 are cleaved into S1 and S2 subunits (Kirchdoerfer et al., [@B35]). S2 does not interact with the receptor but it harbors the functional elements required for membrane fusion of the virion. The S1 protein/receptor interaction is the pivotal determinant for SARS-CoV-2 to infect a host species. S1 contains the receptor binding domain (RBD) and directly binds to the peptidase domain (PD) of ACE 2 to gain entry into host cells (Turner et al., [@B75]; Li et al., [@B41]; Yan et al., [@B87]). Despite high similarity between the RBD of SARS-CoV and SARS-CoV-2, several amino acid variations are observed in the middle of the binding domain of SARS-CoV-2, which provide an increased affinity to bind to ACE2 more effectively (Wang Q. et al., [@B81]; Yan et al., [@B87]). Peptidase activity of ACE2 is critical for the virion to gain access into the host cytosol. Similar to SARS-CoV, proteolytic cleavage of S1 containing the receptor binding domain (RBD) at the C-terminus of S1 protein of SARS-CoV-2 is required to initiate interaction with PD of the ACE2 receptor (Li et al., [@B40]; Yan et al., [@B87]). Cleavage of S1 protein is achieved by acid-dependent proteolytic cleavage by one or several host proteases, including cathepsins, transmembrane protease serine protease (TMPRSS)2, TMPRSS4, or human airway trypsin-like protease (Hoffmann et al., [@B28]). The exact protease has not been identified. Proteolytic cleavage is followed by fusion of the viral and cellular membranes. Furthermore, it has been shown that S protein cleavage occurs at two different sites within the S2 portion of the protein, with the first cleavage important for separating the RBD and fusion domains of the S protein and the second for exposing the fusion peptide (cleavage at S2′) (Belouzard et al., [@B4]). Binding of S1 to the ACE2 receptor triggers the cleavage of ACE2 by a disintegrin and metallopeptidase domain 17 (ADAM17)/tumor necrosis factor-converting enzyme (TACE) at the ectodomain sites (Lambert et al., [@B38]; Heurich et al., [@B27]; Oarhe et al., [@B57]). Additionally, TMPRSS2 cleaves ACE2 at the intracellular C-terminal domain (Heurich et al., [@B27]; Hoffmann et al., [@B28]). Both cleavages (ectodomain and endodomain) by ADAM17 and TMPRSS2 facilitate effective cellular viral entry. It appears that this process leads to shedding of host ACE2 receptor (Belouzard et al., [@B4]) that may contribute to the loss of ACE2 function and systemic release of S1/ACE2 complex.

Generally fusion with the host plasma membrane occurs within acidified endosomes that requires cleavage at S2′ exposing a fusion peptide that inserts into the membrane. The potential beneficial effect of chloroquine on SARS-CoV-2 is due to its effect on the endosomal uptake and acidification. The process of fusion with the host membrane is followed by the formation of a funnel like structure built by two heptad repeats in the S2 protein in an antiparallel six-helix bundle facilitating the fusion and release of the viral genome into the cytoplasm. The viral replication genome of CoVs contains a variable number (World Health Organization, [@B84]; Lu et al., [@B45]; Porcheddu et al., [@B60]; Sohrabi et al., [@B71]; Zhou et al., [@B88]; Baud et al.) of open reading frames (ORFs). Two-thirds of viral RNA, mainly located in the first ORF (ORF1a/b) translates two polyproteins, pp1a and pp1ab, and this encodes 16 non-structural proteins (NSP), while the remaining ORFs encode accessory and structural proteins (Fehr and Perlman, [@B14]). The rest of the virus genome encodes four essential structural proteins, including spike (S) glycoprotein, small envelope (E) protein, matrix (M) protein, and nucleocapsid (N) protein (Fehr and Perlman, [@B14]). After replication and subgenomic RNA synthesis, the viral structural proteins, S, E, and M are translated and inserted into the endoplasmic reticulum (ER), followed by movement along the secretory pathway into the endoplasmic reticulum-Golgi intermediate (Krijnse-Locker et al., [@B37]; Fehr and Perlman, [@B14]). The M protein directs most protein-protein interactions. For assembly of virus, the interaction of M protein with E protein is required to form Virus-Like Particles (VLPs), suggesting these two proteins function together to produce coronavirus envelopes.

Mechanism of Disease {#s3}
====================

Effect of SARS-CoV-2 Infection on Renin/Angiotensin System
----------------------------------------------------------

Because of the central role of ACE2 receptor as the viral entry point, the understanding of the functional role of ACE/angiotensin receptor (AT) and ACE2/MAS receptor is critical for the understanding of the pathophysiological changes due to SARS-CoV-2 infection. Understanding of the molecular downstream effects of angiotensin (Ang) on cellular signaling may explain the observed clinical picture of severe respiratory distress, myocardial injury, renal failure, and increased mortality due to SARS-CoV-2 infection among the aging population and subjects with cardiovascular and metabolic diseases (Zhou et al., [@B88]; Zhu et al., [@B89]).

ACE Genes
---------

Sequence analysis suggests that ACE and ACE2 exhibit 42% amino acid homology and ACE2 has evolved through gene duplication (Donoghue et al., [@B13]). ACE2 maps to chromosome Xp22, spans 39.98 kb of genomic DNA, and contains 20 introns and 18 exons (Turner et al., [@B75]). The ACE2 gene encodes a type I membrane-bound glycoprotein composed of 805 amino acids (Marian, [@B49]). Functional domains include a C-terminal transmembrane anchoring region (carboxy-terminal domain), N-terminal signal peptide region and an HEXXH zinc binding metalloprotease motif (catalytic domain) (Li et al., [@B41]; Cerdà-Costa and Xavier Gomis-Rüth, [@B6]). ACE receptors are expressed in almost all tissues, while ACE2 is expressed on alveolar epithelial cells and capillary endothelial cells. ACE2 is highly expressed in capillary rich organs such as lungs and kidneys but also in the gut and brain (Hamming et al., [@B25]; Tikellis and Thomas, [@B74]; Roca-Ho et al., [@B64]). Genetic polymorphisms of ACE and ACE2 are associated with hypertension, cardiovascular disease, stroke, and diabetes (Crackower et al., [@B10]; Ramachandran et al., [@B62]; Jang and Kim, [@B32]; Fehr and Perlman, [@B14]). Despite the structural homology between ACE and ACE2, they have divergent physiological function. ACE regulates the Renin Angiotensin Aldesterone system (RAS). ACE2 counterbalances the deleterious effect of the ACE/RAS pathway through its downstream ACE2/Angiotensin (1-7)/MAS axis. The critical role of RAS has been shown in the pathogenesis of metabolic inflammatory diseases (de Kloet et al., [@B11]). Classical activation of angiotensin II depends on renin and ACE activity. Prorenin (a 46KD protein) is the inactive precursor of renin. Upon activation of the juxtaglomerular apparatus (JG) of the afferent arterioles of the kidneys, specialized proteases cleave prorenin to renin. Once renin is released into the blood, it cleaves angiotensinogen into angiotensin (Ang) I. Ang I is physiologically inactive, but acts as a precursor of Ang II. The conversion of Ang I to Ang II is catalyzed by ACE. ACE is expressed primarily in the vascular endothelium of the lungs and kidneys (Wakahara et al., [@B79]), but also on the epithelium of the lungs and upper respiratory system. After Ang I is converted to Ang II, it binds to angiotensin II type I (AT) and type II receptors in the kidney, adrenal cortex, arterioles, and the brain ([Figure 1A](#F1){ref-type="fig"}). Ang II acts on the adrenal cortex to stimulate the release of aldosterone (Xue et al., [@B85]), leading to sodium and water retention. While the effects of Ang II are rapid, the effects of aldosterone are retarted due to slower effects on downstream targeted gene transcription. The overall physiological net effects of RAS activation is an increase in total body sodium, total body water, and increased vascular tone. Furthermore, the binding of Ang II to AT receptors results in vasoconstriction (Gustafsson and Holstein-Rathlou, [@B24]), endothelial injury (Watanabe et al., [@B83]), endovascular thrombosis (Tay and Lip, [@B73]) and increase blood volume. Increased Ang II is associated with hypertension and accelerated thrombosis in arterioles by activating the coagulation cascade (both thrombin and platelets) (Senchenkova et al., [@B68]; Singh and Karnik, [@B70]). Interestingly, the thrombogenic effects of AngII on the platelets was not reversible by application of aspirin (Jagroop and Mikhailidis, [@B31]). At the cellular level, angiotensin II induces various signaling pathways, including serine/threonine kinase, ERK, JNK/MAPK as well as PKC (Malhotra et al., [@B48]). Studies have shown that Ang II effectively induces IL-6 and TNF-α, possibly through serine tyrosine kinases, ERK/JNK MAPK activation, G protein coupled receptor activation or through interaction with mineralocorticoid receptors (Funakoshi et al., [@B17]; Han et al., [@B26]; Ruiz-Ortega et al., [@B65]; Luther et al., [@B46]). Ang II is a potent activator of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and hence an inducer of reactive oxygen species (ROS) production (Garrido and Griendling, [@B18]). Furthermore, Ang II activates neutrophils and macrophages flux to the affected tissues and inhibits the production of nitric oxide and hence promotes vascular injury (Kato et al., [@B34]; Nabah et al., [@B55]). These considerations provide new visions to develop targeted therapies, as Ang II functions as a pluripotent mediator to enhance cytokines (IL-6, TNFα, and others), oxidative injury by ROS, endothelial injury by inhibiting NO synthesis and vasoconstriction. Therefore, inhibition of only one of its targets for instance IL-6 may not provide significant therapeutic benefit in these patients. Currently, there is an ongoing clinical trial to study the effect of monoclonal antibodies against IL-6 receptor ([ClinicalTrials.gov](https://www.ClinicalTrials.gov) Identifier: NCT04317092).

![Dysregulation of Ang II and Ang (1-7) by loss of protective function of ACE2 receptor. **(A)** under physiological condition there is a balance in ACE and ACE2 receptor activity. ACE regulates the Renin Angiotensin Aldosterone system (RAS) and cleaves Ang I to produce Ang II. Ang II is a potent vasoconstrictor and detrimental for endothelial and epithelial function through activating AT1 and AT2 receptors. The counterbalance of the RAS/Ang II output is regulated by ACE2 and Mas/G protein coupled receptor activity. ACE2 cleaves Ang I and Ang II into Ang-1-9 and Ang1-7, respectively, thereby it activates MAS/G protein coupled receptor that protect cell death. **(B)** SARS-CoV-2 binds to ACE2 to gain entry to epithelial cells of the lungs. Cleavage of spike proteins by a protease such as trypsin/cathepsin G and or ADAM17 on ectodomain and TMPRSS2 of endodomain sites facilitate viral entry into the cells. This process leads to shedding of host ACE2 receptors and loss of its protective function. Loss of function of ACE2 activity prevents production of Ang 1-9 and Ang1-7. Lack of Ang1-7 diminishes the activity of MAS/G receptor, leading to the loss of its protective functions including vasodilatation, cell protection both at the epithelial and endothelial sites. Loss of ACE2 function leads to an imbalance and unchecked effects of Ang II and upregulation of RAS/Ang II pathway. Upregulation of Ang II leads to vasoconstriction, thrombophilia, microthrombosis, alveolar epithelial injury and respiratory failure. Therefore, inhibiting the proteolytic function of trypsin/cathepsin and ADAM17 or TMPRSS2 and or direct activation of MAS/G receptor by enhancing Ang-(1-7) can overcome the loss of function ACE2 and are viable targets to prevent tissue damage to the host.](fcimb-10-00317-g0001){#F1}

It is very important to note, especially in the context of SARS-CoV-2 infection, that besides the classical RAS/ACE mediated Ang II formation, formation of Ang II can occur through alternative pathways by various proteases. These include tryptensin, cathepsin G, tonin, kallikrein, neutral endopeptidase, and chymase ([Figure 1A](#F1){ref-type="fig"}). These proteases can cleave Ang I to form Ang II (Kramkowski et al., [@B36]; Lorenz, [@B44]; Becari et al., [@B3]; Uehara et al., [@B76]). Most of these proteases are localized in specific tissues (lungs, myocardium, arterioles, kidney, or brain) and are not sensitive to ACE inhibitors. Interestingly, targeted inhibition of ACE using ACE inhibitors, only decreased Ang II levels for a short period of time, and Ang II levels return to baseline 1 week after treatment with ACE inhibitors (Mento and Wilkes, [@B52]). Furthermore, it has been shown that application of ACE and Ang II receptor blocker (ARB) inhibitors in animal models leads to an increase in the expression of ACE2 (Ishiyama et al., [@B30]). Part of protective function of ACE and ARBs is considered to be due to upregulation of ACE2. Therefore, it is possible that upregulation of ACE2 may provide more available receptors for viral entry and hence a higher viral load associated with poor prognosis (Chu et al., [@B8]). This also suggests that in subjects, who are on ACE inhibitors, the activation of alternative pathways may play a significant role in the formation of Ang II (Diaz, [@B12]). Currently, a clinical trial is ongoing to assess the effect of ACE/ARB inhibitors ([ClinicalTrials.gov](https://www.ClinicalTrials.gov) Identifier: NCT04330300) on SARS-CoV-2 infection. If the alternative pathways in the formation of Ang II are important, it is highly unlikely that the ACE/ARB inhibitors play a role on the clinical course of SARS-CoV-2 infection.

ACE2 acts as a ligand through its recently identified MAS1 receptor, which is a G-protein--coupled receptor (Donoghue et al., [@B13]; Santos et al., [@B66]). ACE2 is a monocarboxypeptidase, which cleaves Ang I into a non-apeptide, Ang 1-9 and Ang II into a heptapeptide, Ang 1-7 (Santos et al., [@B66]; Marian, [@B49]). Both peptides have vasodilatory and antiproliferative and protective functions by activating the MAS/G receptor. The ACE2/Ang 1-7/MAS1 axis provides an endogenous counter-regulatory mechanism within the renin--angiotensin system (RAS) that balances the deleterious effects of the ACE/Ang II/AT1 receptor axis (Santos et al., [@B66]). Mice deficient in MAS1 or ACE2 receptors exhibit cardiac systolic dysfunction, increased blood pressure, myocardial interstitial fibrosis, endothelial dysfunction, and exhibit increased susceptibility to intravascular thrombosis, chronic kidney disease, metabolic abnormalities, and various other biological abnormalities that regulate the cardiovascular system (Yamamoto et al., [@B86]; Tikellis and Thomas, [@B74]). ACE2 activation prevents the deleterious effects of Ang II on the cells and organisms, such as cell death, fibrosis, angiogenesis, and thrombosis formation (Fraga-Silva et al., [@B16]; Tikellis and Thomas, [@B74]). Recent autopsy results on SARS-CoV-2 infected humans showed diffuse alveolar damage with massive capillary congestion accompanied by microthrombi in vascular beds but a paucity of inflammatory infiltrates (Menter et al., [@B51]). However, pathological examination on autopsies have not investigated if SARS-CoV-2 infection leads to total destruction of ACE2 receptors on the alveolar epithelial and endothelial cells. Interestingly, in an animal model of SARS-CoV, Oudit et al. found a marked decreased ACE2 expression in the heart of infected mice (Oudit et al., [@B58]). The key product of ACE2 activity is Ang-(1-7), which is considered a biologically active member of the RAS. By binding to MAS, it induces many beneficial actions, such as vasodilation, inhibition of cell growth, and protection from alveolar epithelial cell injury. In addition, it has antifibrotic, anti-thrombotic, and antiarrhythmogenic effects (le Tran and Forster, [@B39]; Schindler et al., [@B67]; Li et al., [@B42]). It has been shown that the ACE2-Ang-(1-7)-MAS axis has a protective effect on the brain and prevents ischemic stroke (Jiang et al., [@B33]).

Direct Protective Actions of ACE2 on Lung Alveolar Epithelial Cells
-------------------------------------------------------------------

In addition to its protective role in the cardiovascular system, ACE2 has a direct protective role in alveolar epithelial cells. In the lungs ACE2 has numerous physiological functions, most of which are protective against lung injury. Similar to the endothelial site, ACE2 degrades the octapeptide Ang II by removing a single amino acid from the C-terminal end of the peptide to generate the heptapeptide Ang1-7. Our laboratory and others have shown that ACE2 protects against lung injury by: (a) degrading Ang II, which is vasoconstrictive and proapoptotic for lung epithelial cells (Wang et al., [@B82]) and profibrotic (Li et al., [@B42]; Uhal et al., [@B77]), and (b) by producing the peptide Ang1-7, which inhibits the actions of Ang II through binding to the MAS receptor (Gopallawa and Uhal, [@B20]). In support of this protective role for ACE2, pharmaceutical preparations of recombinant ACE2, when administered to experimental animals, protect against lung cell death, inhibit acute lung injury and prevent lung fibrosis after chronic injury to the lungs (Li et al., [@B42]; Rey-Parra et al., [@B63]). As further evidence, the application of a specific competitive inhibitor of ACE2, DX600, to primary cultures of isolated ACEs increases the level of Ang II released into the serum-free culture medium by autocrine mechanisms, reduces the amount of released Ang1-7 and, importantly, induces apoptosis inhibitable by the AT1 receptor blocker (Menter et al., [@B51]). Thus, functional ACE2 normally expressed by alveolar epithelial cells can be viewed as a critical survival factor for these lung cells. In addition, the enzymatic product of ACE2, the Ang1-7, itself protects against lung cells death by antagonizing that actions of Ang II (le Tran and Forster, [@B39]). If Ang1-7 is applied to cultures of lung epithelial cells, it can prevent lung cell death in response to either Ang II or the ER stress inducer MG132 (Nguyen and Uhal, [@B56]). The Ang1-7 receptor MAS and the JNK-selective phosphatase MKP-2 appear to be critical in this protective action of Ang1-7 response, becauses iRNAs or antisense knockdowns of MAS or MKP-2 can eliminate the ability of Ang1-7 to prevent lung cell death (Gopallawa and Uhal, [@B21]). Indeed, Ang1-7 itself and congeners of the peptide, such as cyclic Ang1-7 (Gopallawa and Uhal, [@B21]), have already been shown to protect the lungs in preclinical models of acute lung injury (Simoes e Silva et al., [@B69]; Gopallawa and Uhal, [@B20]).

Therapeutic Strategies for SARS-CoV-2 Infection
-----------------------------------------------

Currently, there are no targeted drugs specifically against SARS-CoV-2. Recent efforts have been put forward of drug repurposing by screening of various available antiviral agents with the aim to identify possible treatments. Among those, lopinavir, originally used for treatment of human immunodeficiency virus, was identified to have potential antiviral activity against SARS-CoV-2. Unfortunately, a randomized-controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection showed no benefit of lopanavir (Cao et al., [@B5]). Other studies suggested that remdesivir (GS5734) an inhibitor of RNA polymerase, originally developed to treat Ebola infections, has *in vitro* activity against multiple RNA viruses, including SARS-CoV-2 (Mulangu et al., [@B54]). Experimental data suggested that at micromolar concentration of remdesivir and chloroquine potentially blocked virus infection (Wang M. et al., [@B80]). Current clinical trials are ongoing to assess the efficacy of remdesivir treatment alone or in conjunction with chloroquine in SARS-CoV-2 infection. Because hydroxychloroquine and chloroquine are considered inhibitors of endosomal trafficking of SARS-CoV-2, these drugs are used as potential therapeutics. Both drugs are antimalarial drugs that are also used as antiinflammatory drugs in various autoimmune diseases, including rheumatoid arthritis, Lupus erythematosus, and respiratory diseases such as sarcoidosis (Martin et al., [@B50]; Talreja et al., [@B72]). Despite the high media coverage, currently, there are no randomized clinical trials to support their efficacy against SARS-CoV-2 infection. However, it is conceivable that their efficacy may vary in different stages of virion life cycle and virus interaction with the host. These drugs may be beneficial in early stages of the infection, when the virus requires endosomal uptake. In fact, during the preparation of this manuscript, several non-randomized clinical trials have suggested a lack of significant efficacy of antimalarial drugs in the treatment of SARS-CoV-2 infection (Magagnoli et al., [@B47]).

Corticosteroids are the most conventional immunosuppressant drugs used to suppress inflammatory responses (Cinatl et al., [@B9]). Although the WHO cautions of their use, they have been widely used despite lack of scientific data. Furthermore, because of the high incidence of arterial hypertension, diabetes, and congestive heart failure in subjects with COVID-19, corticosteroids should be used with caution. It is well-described that corticosteroids potentiate the effect of Ang II and RAS (Ullian et al., [@B78]), hence it is less likely that corticosteroids provide any significant clinical benefit in this clinical scenario.

Manipulation of ACE2/Ang(1-7) and Protease Activity as Novel Therapeutic Targets
--------------------------------------------------------------------------------

Considering the significant SARS-CoV-2 related risk factors for hospitalization and mortality among patients with metabolic diseases, including obesity, arterial hypertension, cardiovascular diseases, and diabetes that may reflect overall activation of the RAS system, modulation of RAS activation through the ACE2/(Ang1-7)/MAS pathway should be considered for treatment of this disease. Furthermore, our clinical observation and published clinical data suggest a unique clinical presentation of SARS-CoV-2 patients: most patients present with relatively preserved hemodynamics and lack of lactic acidosis. But they have respiratory distress, appear to be in a hypercoagulable state (Liu et al., [@B43]; Menter et al., [@B51]), exhibit progressive renal failure (Cheng et al., [@B7]), have stroke like features and myocardial injury (Zhou et al., [@B88]). Clinical observational studies indicate that in most cases the respiratory distress occurs many days (in general about 14 days) after the infection, suggesting that this may not be a direct effect of the initial viral infection but rather the hosts reaction to the loss of function of ACE2 and dysregulation of Ang II/ACE2 pathways as well activation of host proteases. Our central hypothesis is that the binding of the coronavirus spike protein to ACE2 leads to shedding of ACE2 receptors by various proteases, which in turn leads to the loss of protective function of the ACE2/MAS axis in the lungs and other organs ([Figure 1B](#F1){ref-type="fig"}). In addition to the loss of protective function of ACE2/MAS, activation of classical pathway (ACE/RAS/Ang II) and alternative pathways through tissue specific proteases, including cathepsins, chymase-like proteases, leads to an excessive production of Ang II at the tissue level. This process may further shift the balance of protective Ang (1-7)/MAS and ACE2 function to the detrimental effects of increased Ang II contributing to lung epithelial and endovascular injury. Therefore, induction of the downstream pathway of ACE2, by activating the ACE2/Ang1-7/MAS axis may prove a useful strategy in preventing lung and cardiovascular damage associated with SARS-CoV-2 infections. Because decreased ACE2/MAS activity augments the Ang II/AT1R activity and its hazardous consequence on increased pulmonary vascular endothelial/epithelial injury and lung pathology. Inhibiting the activity of proteases necessary for cleavage of viral spike proteins: for instance inhibition of enzymatic activity of ADAM17 and TMPRSS2 could serve as other novel therapeutic targets. This could potentially block viral interaction with the receptor and its entry into the cells. Identification of specific proteases and development of inhibitors targeting proteases necessary for cleavage of spike proteins may prove to be viable. In addition, exploiting the protective effect of Ang1-7 or its analogs, such as AVE0991 AVE0991 (Pinheiro et al., [@B59]) against deleterious effect of increased Ang II is feasible and might be effective for the symptomatic treatment of these patients.

Concluding Remarks {#s4}
==================

Based on the importance of ACE2 as a counterbalance to the deleterious effects of Ang II, the loss of ACE2 and Ang(1-7) may be detrimental to the organism. Surprisingly, little is known about the effect of SARS-CoV-2 virus binding to ACE2 and how the viral binding on this receptor may modulate the ACE2 enzymatic activity impact its role as a "survival factor." Critical questions that are yet to be answered include: (1) What effect does SARS-CoV-2 binding to ACE2 have on its enzymatic activity, and on its protective actions toward lung epithelial cells and lung injury? (2) What effect(s) does SARS-CoV-2 infection of lung epithelial cells/endothelial cells have on ACE2 expression in the lungs and other organs? (3) Do known inhibitors or activators of ACE2 have any effect(s) on the binding of SARS-CoV-2 to the ACE2 receptor and/or infection of lung epithelial cells? Regardless, these are questions of fundamental importance to our understanding of SARS-CoV-2 biology that need to be answered soon.
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